There has been substantial progress in our understanding of the Idiopathic Inflammatory Myopathies (IIM) in recent years, twinned with an expanding set of possible treatment modalities. Higher level evidence to support treatment decisions is generally slow to emerge or currently absent. This presenter will outline their current approach to therapy across the spectrum of IIM phenotypes.